Novo Nordisk Appeals US Drug Price Challenge to Third Circuit

Novo Nordisk is taking its challenge against the Medicare Drug Price Negotiation Program to the Third Circuit after a federal judge struck down its statutory and constitutional claims.

The Wednesday notice of appeal to the US Court of Appeals for the Third Circuit comes after a federal judge in New Jersey rejected arguments from Novo Nordisk A/S that alleged the Inflation Reduction Act program compels speech, violates separation of powers, and is involuntary.

The appeal was filed a day before the Centers for Medicare & Medicaid Services published the first 10 negotiated drug prices, unveiling $7.5 billion in savings for ...